All In Biotech

Drug Trial Radar · NCT05535959

A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor

A Phase 1, Randomized, Open-label, Crossover Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121, Tezacaftor, and Deutivacaftor in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Dec 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Sep 15, 2022

Primary completion

Nov 9, 2022

Study completion Nov 9, 2022

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Sep 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the relative bioavailability of a fixed-dose combination tablet (FDC) of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA).

Conditions

  • Cystic Fibrosis

Interventions

  • VX-121/TEZ/D-IVADrug

    FDC tablet for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax) of VX-121, TEZ, and D-IVATime frame: Pre-dose up to 288 hours Post-dose
  2. Area Under the Concentration Versus Time Curve (AUC) of VX-121, TEZ, and D-IVATime frame: Pre-dose up to 288 hours Post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON Salt Lake City

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.